Therapy News and Research

RSS

Study: Rural cancer patients cross state lines for specialized care

In a federally funded study, researchers from Huntsman Cancer Institute at the University of Utah (the U) found that 7% of Medicare patients cross state borders for cancer care, and rates were nearly double for those who lived in rural areas.

4 Apr 2025

New approach to combat influenza and herpes with bean-based gum

In today's interconnected world, infectious diseases pose an escalating threat, as demonstrated by the coronavirus pandemic and outbreaks of H1N1, SARS, Ebola, Zika, and H5N1 (bird flu) viruses-all of which have had significant global health and economic impacts.

4 Apr 2025

ChemoID test leads to better outcomes in platinum-resistant ovarian cancer

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ovarian cancer.

4 Apr 2025

Enfortumab vedotin and pembrolizumab show major benefits for urothelial carcinoma patients

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, urothelial carcinomas grow in the bladder (bladder carcinoma).

4 Apr 2025

Triple therapy reduces tumor burden and improves survival in glioblastoma models

A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled "Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT."

4 Apr 2025

CRISPR tool unveils genetic drivers of blood cell maturation

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.

4 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Study: Jumbo phages utilize EPI vesicles to evade bacterial immune response

In a growing global trend, bacteria have evolved new ways to maneuver around medical treatments for a variety of infections. The rising antibiotic resistance crisis poses a significant public health threat in hospitals and other settings, with infections resulting in millions of deaths in recent years.

4 Apr 2025

Reprogramming the colon could be a therapeutic strategy for short bowel syndrome

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine.

3 Apr 2025

Elevated FGF-23 predicts reduced LAAev and stroke risk in patients with atrial fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Current AF management guidelines have introduced the CARE treatment model to strengthen management strategies; in this acronym, the "A" indicates anticoagulation therapy.

3 Apr 2025

New state-of-the-art cancer treatment center opens in Newport Beach

USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has opened Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging, a state-of-the-art radiation oncology and imaging center, at 4590 MacArthur Blvd. in Newport Beach.

3 Apr 2025

OICR funds five innovative cancer drug discovery projects

The Ontario Institute for Cancer Research (OICR) has announced its support for five Ontario research teams working to develop the next generation of medicines that kill tumours more effectively, cause fewer side effects and reduce the risk that cancer will come back.

3 Apr 2025

NUZ-001 shows positive results in human 3D brain model

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results from an independent study undertaken in collaboration with Tessara Therapeutics (“Tessara”) will be presented by the group’s Principal Scientist and Alzheimer’s Disease expert, Dr Mark Greenough at the AD/PD 2025 Advances in Sciences & Therapy conference on April 2nd to 3rd.

3 Apr 2025

4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA

4basebio PLC (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

From 4basebio PLC 3 Apr 2025

New structural and mechanistic understanding for cancer drug design

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and protects replicating DNA in dividing cells. This new structural and mechanistic understanding of the RAD52-DNA complex may help researchers develop new anti-cancer drugs.

3 Apr 2025